Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SANGUINE CORP. (SGNC) -- Ignore unavailable to you. Want to Upgrade?

To: Jim B who wrote (4070)	9/18/1998 9:42:00 PM
From: Profiteer	Read Replies (2) \| Respond to of 5402

Jim, wish I had more details for you on that note.. sorry!.However, I do know that Sanguine must be gearing up for more exposure in the future. Dr. Drees is making a new video for release to the media. It is very professionally done using a University Laboratory for the background setting.. No word on if it will be available to the general public.

To: Jim B who wrote (4070)	9/18/1998 11:06:00 PM
From: Kevin Clarke	Respond to of 5402

JIM I'm going to tape both interviews so I won't miss a thing. And I hope this helps you with your question Public Information Campaign Underway for Developer of Synthetic Blood Substitute PASADENA, Calif.--(BUSINESS WIRE)--Aug. 26, 1998--Dr. Thomas C. Drees, president and chief executive officer of Sanguine Corp. (OTC BB:SGNC), Wednesday announced the launch of a public information campaign to inform the public about the worldwide need for a blood substitute, and the company's own collaborative research with Battelle Memorial Research Institute to develop a viable synthetic blood product. Salt Lake City-based Smith Consulting Services (SCS), one of Sanguine's principal shareholders, has retained mkl/public relations (mkl/pr) as agency of record to develop the campaign and to update investors and shareholders on current activity and progress. According to Mary Kay Lazarus, mkl/pr president, the agency welcomes the assignment to increase awareness of the significant worldwide blood supply shortages as well as the growing risk of blood-borne diseases. "Dr. Drees' leadership in more than 20 years of blood substitute research and in the development of the only blood substitute to gain FDA approval provide significant opportunity for public dialogue about this critical issue and the significance of Sanguine's research," commented Lazarus. The PR agency specializes in national and international business press and media coverage; mkl/pr clients include ASARCO, EURO RSCG/DSW Partners, Iomega, and First Security Bank. CONTACT: WOW.....Dr Drees must have something REAL BIG to say,to come out on two MAJOR PROGRAMS back to back like this.

To: Jim B who wrote (4070)	9/21/1998 3:26:00 PM
From: mkl/public relations	Read Replies (4) \| Respond to of 5402

How Did SCGN Get On CNNfn and AHN??? Mkl/pr was able to arrange for Dr. Drees to appear on both television spots. The agency approached both networks first, via fax and second, via phone. Publicity arranged by a PR agency is not paid for. Paid for publicity has its own name: Advertising. CNNfn and AHN were both very interested in the synthetic blood topic and that's why they agreed to have Dr. Drees as a guest.